GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Xvivo Perfusion AB (FRA:3XV) » Definitions » Intrinsic Value: Projected FCF

Xvivo Perfusion AB (FRA:3XV) Intrinsic Value: Projected FCF : €5.03 (As of May. 15, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Xvivo Perfusion AB Intrinsic Value: Projected FCF?

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.

As of today (2024-05-15), Xvivo Perfusion AB's Intrinsic Value: Projected FCF is €5.03. The stock price of Xvivo Perfusion AB is €32.65. Therefore, Xvivo Perfusion AB's Price-to-Intrinsic-Value-Projected-FCF of today is 6.5.

The historical rank and industry rank for Xvivo Perfusion AB's Intrinsic Value: Projected FCF or its related term are showing as below:

FRA:3XV' s Price-to-Projected-FCF Range Over the Past 10 Years
Min: 3.22   Med: 6.89   Max: 12.1
Current: 6.49

During the past 12 years, the highest Price-to-Intrinsic-Value-Projected-FCF of Xvivo Perfusion AB was 12.10. The lowest was 3.22. And the median was 6.89.

FRA:3XV's Price-to-Projected-FCF is ranked worse than
91.32% of 357 companies
in the Medical Devices & Instruments industry
Industry Median: 1.78 vs FRA:3XV: 6.49

Xvivo Perfusion AB Intrinsic Value: Projected FCF Historical Data

The historical data trend for Xvivo Perfusion AB's Intrinsic Value: Projected FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xvivo Perfusion AB Intrinsic Value: Projected FCF Chart

Xvivo Perfusion AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Intrinsic Value: Projected FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 3.15 3.73 4.01 5.50

Xvivo Perfusion AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Intrinsic Value: Projected FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.83 3.90 5.20 5.50 5.11

Competitive Comparison of Xvivo Perfusion AB's Intrinsic Value: Projected FCF

For the Medical Devices subindustry, Xvivo Perfusion AB's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Xvivo Perfusion AB's Price-to-Projected-FCF Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Xvivo Perfusion AB's Price-to-Projected-FCF distribution charts can be found below:

* The bar in red indicates where Xvivo Perfusion AB's Price-to-Projected-FCF falls into.



Xvivo Perfusion AB Intrinsic Value: Projected FCF Calculation

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.

The details of how we calculate the intrinsic value of stocks are described in detail here.

This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)

In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)


Add all the Free Cash Flow together and divide 6 will get Xvivo Perfusion AB's Free Cash Flow(6 year avg) = €1.62.

Xvivo Perfusion AB's Intrinsic Value: Projected FCF for today is calculated as

Intrinsic Value: Projected FCF=(Growth Multiple*Free Cash Flow (6 year avg)+Total Stockholders Equity (Mar24)*0.8)/Shares Outstanding (Diluted Average)
=(14.862653310476*1.61856+177.009*0.8)/31.499
=5.26

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Xvivo Perfusion AB  (FRA:3XV) Intrinsic Value: Projected FCF Explanation

The growth multiple is capped between 8.35 and 17.74.

Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.

Xvivo Perfusion AB's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as

Price-to-Intrinsic-Value-Projected-FCF=Share Price/Intrinsic Value: Projected FCF
=32.65/5.2593192209976
=6.21

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Xvivo Perfusion AB Intrinsic Value: Projected FCF Related Terms

Thank you for viewing the detailed overview of Xvivo Perfusion AB's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Xvivo Perfusion AB (FRA:3XV) Business Description

Traded in Other Exchanges
Address
Massans gata 10, P.O. Box 53015, Gothenburg, SWE, SE-400 14
Xvivo Perfusion AB is a medical technology company dedicated to extending the life of all major organs so transplant teams around the world can save more lives. Its solutions allow clinicians and researchers to push the boundaries of transplantation medicine. It operates in three segments namely, Thoracic: Sales of lung and heart transplant products, Abdominal: Sales of liver and kidney transplant products. Services: Revenue from sales of services in organ recovery (carried out by subsidiary STAR Teams Inc.). The majority of revenue is derived from the Thoracic segment. Geographically, the majority is from the United States.

Xvivo Perfusion AB (FRA:3XV) Headlines

No Headlines